Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hrBMP4 CED in Recurrent Glioblastoma
NCT02869243Phase 1Completed
- Sponsor
- StemGen
- Start
- Jul 2017
- Primary completion
- Oct 2020
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of bone morphogenetic protein 4 in glioblastoma (GBM), sponsored by StemGen. Primary endpoint: Dose-Limiting Toxicity up to 8 weeks. Started Jul 2017; status: completed.
02
Drugs
bone morphogenetic protein 4
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02869243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869243.